1. Centers for Disease Control and Prevention.
Ten great public health achievements—United States, 1900–1999. MMWR
Morb Mortal Wkly Rep. 1999;48(12):241-243.
2. World Health Organization and United Nations Children’s
Fund. Global Immunization Vision and Strategy, 2006–2015.
http://www.who.int/vaccines/GIVS/.
Accessed January 10, 2008.
3. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity
to common viral and vaccine antigens.
N Engl J Med. 2007;357:1903-1915.
[PubMed: 17989383]
4. Centers for Disease Control and Prevention. Recommended Immunization
Schedules for persons aged 0–18 years—United States,
2009. MMWR Morb Mortal Wkly Rep. 2009;57:Q1-Q4.
5. Centers for Disease Control and Prevention. General recommendations
on Immunization. Recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2006;55(RR15):1-48.
6. Schechter NL, Zempsky WT, Cohen LL, McGrath PJ, McMurtry
CM, Bright NS. Pain reduction during pediatric immunizations: evidence-based
review and recommendations. Pediatrics. 2007;119:e1184-e1198.
9. Varricchio F, Iskander J, Destefano F, et al. Understanding
vaccine safety information from the Vaccine Adverse Event Reporting
System.
Pediatr Infect Dis J. 2004;23(4):287–294.
[PubMed: 15071280]
10. Parker AA, Staggs W, Dayan GH, et al. Implications of a
2005 measles outbreak in Indiana for sustained elimination of measles
in the United States. N Engl J Med. 2006;355(3):447-455.
11. Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of anti-vaccine
movements on pertussis:the untold story. Lancet. 1998;351(9099):356-361.
12. American Academy of Pediatrics. Diekema DS, Committee on
Bioethics. Responding to parental refusals of immunization of children. Pediatrics. 2005;115:1428-1431.
14. Centers for Disease Control and Prevention. Thimerosal in
vaccines: a joint statement of the American Academy of Pediatrics
and the Public Health Service. MMWR Morb Mortal Wkly Rep. 1999;48:563-565.
15. Immunization Safety Review Committee. Institute of Medicine. Immunization
Safety Review: Vaccines and Autism. Washington, DC: National
Academies Press; 2004.
16. Schechter R, Grether JK. Continuing increases in autism
reported to California’s Developmental Services System.
Mercury in retrograde.
Arch Gen Psychiatry. 2008;65:19-24.
[PubMed: 18180424]
17. Pickering LK, Baker CJ. Long SS. McMillan JKA, eds. Red
Book: 2006 Report of the Committee on Infectious Diseases. 27th
ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.
18. Centers for Disease Control and Prevention. Atkinson W,
Hamborsky J, McIntyre L, Wolfe S, eds. 10th ed. Epidemiology
and Prevention of Vaccine-Preventable Diseases. 10th ed.
Washington, DC: Public Health Foundation; 2007.
19. Marshall GS. The Vaccine Handbook: A Practical Guide
for Clinicians. West Islip, NY: Professional Communications;
2008:169-177.
20. Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working
Group. Historical comparisons of morbidity
and mortality for vaccine preventable diseases in the United States.
JAMA. 2007;298:2155-2163.
[PubMed: 18000199]
21. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy
changes and epidemiology of polio in the United States.
JAMA. 2004;292:1696-1701.
[PubMed: 15479934]
22. Centers for Disease Control and Prevention. Poliomyelitis
prevention in the United States: updated recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR
Morb Mortal Wkly Rep. 2000;49(RR-5):1-22.
23. Beasley RP, Hwang L-Y. Epidemiology of hepatocellular carcinoma.
In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral Hepatitis
and Liver Disease. New York: Grune & Stratton; 1984:209-224.
24. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant
hepatitis B vaccine: efficacy with hepatitis B immune globulin in
prevention of perinatal hepatitis B virus transmission.
JAMA. 1987;257:2612-2616.
[PubMed: 2952812]
25. Xu Z-Y, Liu C-B, Francis DP, et al. Prevention of perinatal
acquisition of hepatitis B virus carriage using vaccine: preliminary
report of a randomized, double-blind placebo-controlled and comparative
trial.
Pediatrics. 1985;76:713-718.
[PubMed: 3903646]
26. Centers for Disease Control and Prevention. A comprehensive
immunization strategy to eliminate transmission of hepatitis B virus
infection in the United States. MMWR Morb Mortal Wkly Rep. 2005;54(RR-16);1-23.
27. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination
and the risk of multiple sclerosis
. N Engl J Med. 2001;344:327-332.
[PubMed: 11172163]
28. Halsey NA, Duclos P, Van Damme P, Margolis H. Hepatitis
B vaccine and central nervous system demyelinating diseases.
Pediatr
Infect Dis J. 1999;18:23-24.
[PubMed: 9951975]
29. Stratton K, Almario DA, McCormick MC, eds. Hepatitis
B Vaccine and Central Nervous System Demyelinating Disorders. Washington,
DC: Institute of Medicine, National Academies Press; 2002.
30. Adams WG, Deaver KA, Cochi Sl, et al. Decline of childhood
Haemophilus
influenzae type b (Hib) disease in the Hib vaccine era.
JAMA. 1993;269:221-226.
[PubMed: 8417239]
31. American Academy of Pediatrics. Haemophilus influenzae infections.
In: Pickering LK, Baker CJ. Long SS. McMillan JKA, eds.
Red Book: 2006 Report of the Committee on Infectious Diseases. 27th
ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:310-322.
32. Centers for Disease Control and Prevention. Invasive pneumococcal
disease in children 5 years after conjugate vaccine introduction—eight
states, 1998–2005. MMWR Morb Mortal Wkly Rep. 2008;57(6):144-148.
33. Centers for Disease Control and Prevention. Licensure of
a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for
use among children --Advisory Committee on Immunization Practices
(ACIP), 2010. MMWR 2010;59(09):258-261.
34. Centers for Disease Control and Prevention. Rubella outbreak—Arkansas,
1999. MMWR Morb Mortal Wkly Rep. 2001;50(50):1137-1139.
35. Centers for Disease Control and Prevention. Preventable
measles among US residents, 2001–2004. MMWR Morb
Mortal Wkly Rep. 2005;54(33):817-820.
36. Centers for Disease Control and Prevention. Update: multistate
outbreak of mumps—United States, January 1–May
2, 2006. MMWR Morb Mortal Wkly Rep. 2006;55(20):559-563.
37. Centers for Disease Control and Prevention. Measles, mumps,
and rubella—vaccine use and strategies for elimination
of measles, rubella, and congenital rubella syndrome and control
of mumps: Recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1998;47(RR-8):38-39.
38. Centers for Disease Control and Prevention. Update: recommendations
from the Advisory Committee on Immunization Practices (ACIP) regarding
administration of combination MMRV vaccine. MMWR Morb Mortal
Wkly Rep. 2008;57(10):258-260.
39. Wakefield AJ, Murch SH, Anthony A. Ileal-lymophoid-nodular
hyperplasia and pervasive developmental disorder in children.
Lancet. 1998;351:637-641.
[PubMed: 9500320]
40. Taylor B, Lingan R, Simmons A, Stowe J, Miller E, Andrews
M. Autism and MMR vaccination in North London; no causal relationship. Molec
Psych. 2002;7:S7-S9.
41. Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio
M. No evidence for measles, mumps and rubella vaccine–associated
inflammatory bowel disease or autism in a 14-year prospective study.
Lancet. 1998;351:1327-1328.
[PubMed: 9643797]
42. Forbonne E, Chakrabati S. No evidence for a new variant
of mesasles-mumps-rubella-induced autism. Pediatrics. 2001;108:e54.
43. Halsey N, Hyman S, and The Conference Writing Panel. Measles-mumps-rubella
vaccine and autistic spectrum disorders. Pediatrics. 2001;107
(5):e84-e107.
44. Stratton K, Gable A, Shetty P, McCormick M, eds. Immunization
Safety Review Committee, Board on Health Promotion and Disease Prevention,
Institute of Medicine. Immunization Safety Review: Measles-Mumps-Rubella
Vaccine and Autism. Washington, DC: National Academies
Press; 2001.
45. Wharton M. The epidemiology of varicella zoster virus infections. Infect
Dis Clin North Am. 1996;10(3):571-581.
46. Galil K, Brown C, Lin F, Seward J. Hospitalizations for
varicella in the United States, 1988 to 1999.
Pediatr Infect
Dis J. 2002;21:931-935.
[PubMed: 12394815]
47. Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality:
trends before vaccine licensure in the United States, 1970–1994. J
Infect Dis. 2000;21:383-390.
48. Seward JF, Watson BM, Peterson VL, et al. Varicella disease
after introduction of varicella vaccine in the United States, 1995–2000. JAMA. 2002:287:606-611.
49. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due
to varicella after implementation of varicella vaccination in the
United States.
N Engl J Med. 2005;352:450-458.
[PubMed: 15689583]
50. Vasquez M, LaRussa PS, Gershon AA. Effectiveness over time
of varicella vaccine. JAMA. 2004; 291:851-855.
51. Tugwell BD, Lee LE, Gillette H, Lorber EM, Hedberg K, Cieslak
PR. Chickenpox outbreak in a highly vaccinated school population.
Pediatrics. 2004;113:455-459.
[PubMed: 14993534]
52. Kuter B, Matthew H, Shinefield H, et al. Ten year follow-up
of healthy children who received one or two infections of varicella
vaccine.
Pediatr Infect Dis J. 2004;23:132-137.
[PubMed: 14872179]
53. Michalik DE, Steinberg SP, LaRussa PS, et al. Primary vaccine
failure after one dose of varicella vaccine in healthy children.
J
Infect Dis. 2008;197:944-949.
[PubMed: 18419532]
54. Gershon AA, Takahashi M, Seward JF. Varicella vaccine. In:
Plotkin S, Orenstein W, Offit P, eds. Vaccines. Philadelphia,
PA: Saunders Elsevier; 2008:915-958.
55. Centers for Disease Control and Prevention. Prevention of
varicella. Recommendations of Advisory Committee on Immunization
Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2007;56(RR-04):1-40.
56. American Academy of Pediatrics, Committee on Infectious
Diseases. Prevention of varicella: recommendations for use of varicella
vaccines in children, including a recommendation for a routine 2-dose
varicella immunization schedule. Pediatrics. 2007;120:221-231.
57. Centers for Disease Control and Prevention. Prevention of
hepatitis A though active or passive immunization: Recommendations
of Advisory Committee on Immunization Practices (ACIP). MMWR
Morb Mortal Wkly Rep. 2006; 55(RR-7):1-23.
58. American Academy of Pediatrics, Committee on Infectious
Diseases. Hepatitis A vaccine recommendations. Pediatrics. 2007;120:189-199.
59. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification
of an outbreak of influenza in Tecumseh, Michigan by vaccination
of schoolchildren.
J Infect Dis. 1970;122:16-26.
[PubMed: 5433709]
60. Neuzil KM, Dupont WD, Wright PF, et al. Efficacy of inactivated
and cold-adapted vaccines against influenza A infection, 1985 to
1990: the pediatric experience.
Pediatr Infect Dis J. 2001;20:733-740.
[PubMed: 11734733]
61. Ritzwoller DP, Bridges CB, Sheetterly S, et al. Effectiveness
of the 2003–04 influenza vaccine among children 6 months
to 8 years for 1 versus 2 doses.
Pediatrics. 2005;116:153-159.
[PubMed: 15995046]
62. Shuler C, Iwamoto M, Neeman R, et al. Influenza vaccine
effectiveness against laboratory-confirmed influenza among children
age 6 to 59 months—Georgia, 2003–2004 [Poster #1008]. Presented
at the 43rd Annual Meeting of the Infectious Diseases Society of
America, San Francisco, CA; 2005.
63. Belshe RB, Mendelmean PM, Treanor J, et al. The efficacy
of live-attenuated, cold-adapted, trivalent, intranasal influenza
vaccine in children.
N Engl J Med. 1998;338:1405-1412.
[PubMed: 9580647]
64. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination
with live-attenuated, cold-adapted, trivalent, intranasal influenza
virus vaccine against a variant (A/Sydney) not contained
in the vaccine.
J Pediatr. 2000;136: 168-175.
[PubMed: 10657821]
65. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative
efficacy of live attenuated influenza vaccine compared with inactivated influenza
vaccine in young children with recurrent respiratory tract infections.
Pediatr
Infect Dis J. 2006;25:870-879.
[PubMed: 17006279]
66. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated
versus inactivated influenza vaccine in infants and young children.
N
Engl J Med. 2007;356:685-96.
[PubMed: 17301299]
67. Centers for Disease Control and Prevention. Prevention and
control of influenza. Recommendations of the Advisory Committee
on Immunization Practices (ACIP), 2008. MMWR Morb Mortal
Wkly Rep. 2008;57(RR-07):1-60.
68. Centers for Disease Control and Prevention. Withdrawal of
rotavirus vaccine recommendations. MMWR Morb Mortal Wkly
Rep. 1999;48: 1007.
69. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception
among infants given an oral rotavirus vaccine.
N Engl J
Med. 2001;344:564-572.
[PubMed: 11207352]
70. Vesikari T, Matson DO, Dennehy P, and the Rotavirus Efficacy
and Safety (REST) Trail Team. Safety and efficacy of a pentavalent human-bovine
(WC3) reassortant rotavirus vaccine. N Eng J Med. 2006;345:23-33.
71. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human
rotavirus vaccine against rotavirus gastroenteritis during the first
2 years of life in European infants: randomized, double-blind controlled
study
. Lancet. 2007;370:1757-1763.
[PubMed: 18037080]
72. Centers for Disease Control and Prevention. Prevention of
rotavirus gastroenteritis among infants and children. Recommendations
of the Advisory Committee on Immunization Practices. MMWR Morb
Mortal Wkly Rep. 2006;55 (RR-12):1-13.
73. Advisory Committee on Immunization Practices. ACIP provisional recommendations for the prevention of rotavirus gastroenteritis
among infants and children.
http://www.cdc.gov/mmwr/PDF/rr/rr5802.pdf. Accessed 10-15-2009.
74. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety
and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.
N
Engl J Med. 2006;354:11-22.
[PubMed: 16394298]
75. Fishbein DB, Broder KR, Markowitz L, Messonier N. New, and
some not-so-new, vaccines for adolescents and diseases they prevent. Pediatrics. 2008;121:S5-S14.
76. Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis
vaccination strategies beyond infancy: recommendations by the global
pertussis initiative.
Clin Infect Dis. 2004;39:1802-1809.
[PubMed: 15578403]
77. Centers for Disease Control and Prevention. Preventing tetanus,
diphtheria and pertussis among adolescents: use of tetanus and diphtheria
toxoids and acellular pertussis vaccines. Recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR Morb
Mort Wkly Rep. 2006;55(RR-03):1-34.
78. American Academy of Pediatrics. Committee on Infectious
Diseases. Prevention of pertussis among adolescents: recommendations
for use of tetanus toxoid, reduced diphtheria toxoid, and acellular
pertussis (Tdap) vaccine. Pediatrics. 2006;117(3):965-978.
79. Halperin S, Sweet L, Baxendale D. How soon after prior tetanus-diphtheria
vaccination can one give an adult-formulation tetanus-diphtheria
pertussis vaccine?
Pediatr Infect Dis J. 2006;25:195-200.
[PubMed: 16511379]
80. Centers for Disease Control and Prevention. Prevention and
control of meningococcal disease: recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR Morb Mortal
Wkly Rep. 2005;54(RR-7):1-21.
81. Centers for Disease Control and Prevention. Revised recommendations
of the Advisory Committee on Immunization Practices to vaccinate
all persons aged 11–18 years with meningococcal conjugate
vaccine. MMWR Morb Mortal Wkly Rep 2007;56:794-795.
82. Centers for Disease Control and Prevention. Updated recommendations
from the Advisory Committee on Immunization Practices (ACIP) for revaccination
of persons at prolonged risk for meningococcal disease. MMWR 2009;58(37): 1042-1043.
83. Centers for Disease Control and Prevention. Update: Guillain-Barré syndrome
among recipients of Menactra meningococcal conjugate vaccine—United
States, June 2005–September 2006. MMWR Morb Mortal
Wkly Rep. 2006;55:1120-1124.
84. Weinstock H, Berman S, Cates W Jr. Sexually transmitted
diseases among American youth: incidence and prevalence estimates,
2000
. Perspect Sex Reprod Health. 2004;36:6-10.
[PubMed: 14982671]
85. Centers for Disease Control and Prevention. FDA licensure
of bivalent human papillomavirus vaccine (HPV2, Cervarix) for sue
in females and updated HPV vaccine recommendations from the Advisory
Committee on Immunization Practices (ACIP). MMWR 2010;59(20):626-632.
86. Centers for Disease Control and Prevention. FDA licensure
of quadrivalent human papillomavirus vaccine (HPV4, Gardasil for
use in males and guidance from the Advisory Committee on Immunization
Practices (ACIP). MMWR 2010;59(20):630-632.